首页> 外文期刊>Diabetes care >Systematic assessment of etiology in adults with a clinical diagnosis of young-onset type 2 diabetes is a successful strategy for identifying maturity-onset diabetes of the young
【24h】

Systematic assessment of etiology in adults with a clinical diagnosis of young-onset type 2 diabetes is a successful strategy for identifying maturity-onset diabetes of the young

机译:对成年人的病因进行系统的临床诊断,对年轻的2型糖尿病进行临床诊断是确定年轻的成熟型糖尿病的成功策略

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE - Misdiagnosis of maturity-onset diabetes of the young (MODY) remains widespread, despite the benefits of optimized management. This cross-sectional study examined diagnostic misclassification of MODY in subjects with clinically labeled young adult-onset type 1 and type 2 diabetes by extending genetic testing beyond current guidelines. RESEARCH DESIGN AND METHODS - Individuals were selected for diagnostic sequencing if they displayed features atypical for their diagnostic label. From 247 case subjects with clinically labeled type 1 diabetes, we sequenced hepatocyte nuclear factor 1 α (HNF1A) and hepatocyte nuclear factor 4 α (HNF4A) in 20 with residual β-cell function ≥3 years from diagnosis (random or glucagon-stimulated C-peptide ≥0.2 nmol/L). From 322 with clinically labeled type 2 diabetes, we sequenced HNF1A and HNF4A in 80 with diabetes diagnosed ≤30 years and/or diabetes diagnosed ≤45 years without metabolic syndrome. We also sequenced the glucokinase (GCK) in 40 subjects with mild fasting hyperglycemia. RESULTS - In the type 1 diabetic group, two HNF1A mutations were found (0.8% prevalence). In type 2 diabetic subjects, 10 HNF1A, two HNF4A, and one GCK mutation were identified (4.0%). Only 47% of MODY case subjects identified met current guidelines for diagnostic sequencing. Follow-up revealed a further 12 mutation carriers among relatives. Twenty-seven percent of newly identified MODY subjects changed treatment, all with improved glycemic control (HbA 1c 8.8 vs. 7.3% at 3 months; P = 0.02). CONCLUSIONS - The systematic use of widened diagnostic testing criteria doubled the numbers of MODY case subjects identified compared with current clinical practice. The yield was greatest in young adult-onset type 2 diabetes. We recommend that all patients diagnosed before age 30 and with presence of C-peptide at 3 years' duration are considered for molecular diagnostic analysis.
机译:目的-尽管优化了治疗方法,但误诊为年轻型糖尿病(MODY)仍然很普遍。这项横断面研究通过将基因检测扩展到当前指南之外,检查了临床标记的年轻成人型1型和2型糖尿病患者中MODY的诊断错误分类。研究设计和方法-如果个体显示出其诊断标签的非典型特征,则选择他们进行诊断测序。从247例临床上标记为1型糖尿病的受试者中,我们对20例肝细胞核因子1α(HNF1A)和肝细胞核因子4α(HNF4A)进行了测序,这些患者在诊断后3年内具有剩余的β细胞功能(随机或胰高血糖素刺激的C -肽≥0.2nmol / L)。从322例临床标记为2型糖尿病的患者中,我们对80例诊断为≤30岁且/或诊断为≤45岁且无代谢综合征的糖尿病中的HNF1A和HNF4A进行了测序。我们还对40名轻度禁食高血糖患者的葡萄糖激酶(GCK)进行了测序。结果-在1型糖尿病组中,发现了两个HNF1A突变(患病率为0.8%)。在2型糖尿病受试者中,鉴定出10个HNF1A,两个HNF4A和一个GCK突变(4.0%)。识别出的MODY病例中只有47%符合当前的诊断测序指南。随访发现亲属中还有12个突变携带者。新发现的MODY患者中有27%改变了治疗方式,所有患者的血糖控制均得到改善(HbA 1c 8.8对3个月时为7.3%; P = 0.02)。结论-与目前的临床实践相比,系统地使用扩大的诊断测试标准使发现的MODY病例的人数增加了一倍。在年轻的成年型2型糖尿病中,产量最高。我们建议对所有在30岁之前被诊断并在3年内存在C肽的患者进行分子诊断分析。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号